-+ 0.00%
-+ 0.00%
-+ 0.00%
Reported Sunday, IDEAYA Nominates IDE101, Potential First-In-Class Dual CDK Inhibitor Targeting CDKN2A-Deficiency In Solid Tumors, With IND Filing Planned For H1 2027
Share
Listen to the news
  • Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combination with inhibitors of RAS and MTAP, including IDEAYA's proprietary Phase 1 PRMT5 inhibitor IDE892
  • CDKN2A-deficiency is a common tumor suppressor loss prevalent in ~10-15% of all solid tumors, including ~70% of pancreatic cancer
  • IDE101's preclinical profile, including combination results with inhibitors of PRMT5 and pan-RAS, will be summarized at IDEAYA's London R&D Day
  • IND-enabling studies underway to support an IND filing in H1 2027
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending